MAAsiRNA

MAAsiRNA develops a pioneering targeted therapy utilizing small interfering RNA (siRNA). After over a decade of intensive interdisciplinary research, they have successfully developed a siRNA-based treatment for Charcot-Marie-Tooth disease type 1A (CMT1A), the most prevalent form of hereditary peripheral neuropathy. Their current objective is to advance towards a patient-ready therapy. Their innovative therapeutic approach has the potential to be adapted for other disorders within the nervous system.